Request Call Back

Contact Us

Case Review Form
*    Denotes required field.

Describe accident or indicate name of drug or device

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Benicar Adverse Reactions

Blood Pressure Drug, Benicar, Linked to Chronic Diarrhea, Other Complications

Blood Pressure Drug, Benicar, Linked to Chronic Diarrhea, Other Complications

Blood Pressure Drug, Benicar, Linked to Chronic Diarrhea, Other Complications

Lawsuits are mounting against drug maker, Daiichi Sankyo Inc., over claims that blood pressure medication, Benicar (olmesartan medoxomil), led to significant adverse reactions, including severe and chronic diarrhea, sprue-like enteropathy, weight loss, malnutrition, and intestinal atrophy.

Forest Laboratories Inc., which allegedly marketed Benicar with Daiichi; Daiichi Sankyo Co. Ltd., Daiichi's Japanese parent company; and other Daiichi entities, has also been named in the lawsuits.

Benicar Injury Lawsuits Mounting

To date, three lawsuits have been brought over Benicar and have been moved to federal court. Additional lawsuits are expected to be filed by the end of this week. The lawsuits allege that Daiichi created Benicar in a defective way and neglected to advise consumers that the medication could lead to:

  • cancer
  • chronic diarrhea
  • nausea
  • dehydration
  • weight loss
  • malnutrition

In one alleged case, a patient required hospitalization for more than 100 days in a four-year period following his having taken Benicar. The man is now being fed by tube, suffered a compression fracture in is back, and developed cataracts in both of his eyes, either due to his having taken Benicar or for diarrhea-related treatments, according to the complaint, wrote Law360.

Federal Regulators Call for Benicar Label Changes Over Intestinal Injuries

In July, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication indicating that it approved label changes that would include intestinal problems—sprue-like enteropathy—that are tied to the blood pressure medication olmesartan medoxomil, which is sold under the names Benicar, Benicar HCT, Azor, and Tribenzor, as well as generic options,

Sprue-like enteropathy causes severe and chronic diarrhea with substantial weight loss and may take months, even years to develop and may require hospitalization. The FDA warns that people who take Benicar who develop these severe intestinal issues with no other cause, should discontinue taking the medication and continue therapy with another anti-hypertensive drug. In patients suffering from sprue-like enteropathy symptoms, discontinuation of Benicar led to clinical improvement of those symptoms.

Benicar is an angiotensin II receptor blocker (ARB) that received FDA approval for the treatment of high blood pressure, either alone or in collaboration with other antihypertensive agents. Sprue-like enteropathy has not been detected with ARB drugs other than olmesartan.

As of July, the agency identified 23 serious patient cases of sprue-like enteropathy in users of Benicar in its adverse event reporting system, according to Law360, which noted that 1.9 million people have filled a prescription for Benicar in 2012.

Many of the patients reporting intestinal injury after taking Benicar had been diagnosed with celiac disease following small intestine biopsies, according to The New York Times/Well blog. Celiac disease is an allergic-like response to the protein, gluten. Biopsies revealed the same injury to that part of the gut mucosa seen in celiac disease, known as celiac sprue. The condition causes destruction to the absorption layer of the gut mucosa, which leads to malabsorption and diarrhea. The difference between celiac disease and the responses seen in people taking Benicar is that Benicar patients do not respond to a gluten-free diet, which is the traditional celiac disease treatment.

Senior FDA Regulator Reveals Cancer Links in ARBs

In 2013, a senior regulator at the U.S. Food and Drug Administration (FDA) sought increased warnings on drugs in the ARB class, according to a prior report by The Wall Street Journal. According to FDA official Thomas A. Marciniak, and other physicians outside of the agency, ARBs may be associated with increased rates of cancer. Dr. Marciniak specialized in cancer while he was a resident at the Mayo Clinic. Before joining the FDA, he spent 10 years at the National Cancer Institute.

A 2010 study published in Lancet Oncology, based on research conducted at University Hospitals in Cleveland, reviewed five studies involving 68,402 patients. The research revealed that, when compared to people not treated with an ARB, individuals taking an ARB experienced an 11 percent increased risk of new cancer overall, and a 25 percent increased risk of new lung cancer.

Although the FDA approved the drugs, indicating that its analysis did not find an increase in cancer risks, Dr. Marciniak did not agree. The FDA conducted a meta-analysis, which means it combined a number of studies so that it could review more patients and increase statistical power. This method was used to locate potential ARB side effects; however, if the original studies contain flaws, then the meta-analysis would compound those flaws. Dr. Marciniak also warned others at the FDA that utilizing results tabulated by companies would likely lead to unreliable results, writing, "Garbage in, garbage out." Dr. Marciniak also wrote, in an internal analysis that The Wall Street Journal viewed, that the FDA meta-analysis did not take into account cases of "lung carcinomas," as lung cancers, which they, in fact, are.

Dr. Marciniak, following the FDA’s dismissal of ARB cancer concerns, went through the raw data on the drug studies, by patient. By March 2013, he found a 24 percent increase in cancer in ARB patients, which he concluded was statistically significant. In fact, in 10 of the 11 studies he reviewed, he found that there were more lung cancer cases in ARB-treated patients than in patients not taking the drugs. "The FDA needs to inform patients and physicians about the ARB lung-cancer risks. The FDA must act now," he wrote in a memo to senior FDA officials, The Wall Street Journal reported. The FDA disagreed; however, others agree. "I have no doubt that ARBs increase cancer risk," Dr. Sipahi, an author of the 2010 study, told The Wall Street Journal. Renowned Cleveland Clinic cardiologist Steven Nissen, also said that the FDA "has a huge advantage over academic researchers, of having access to patient-level data" that it hasn't fully reviewed. "Until I see such a rigorous analysis, I remain concerned about the ARB cancer problems.”

Although Dr. Marciniak's analysis did not include trial data on all ARB drugs, including Benicar, he did conclude "that the increased incidence of lung cancers with ARB use is likely a class effect of ARBs" and that it would be "inappropriate" to classify specific ARBs as being safe because of the "lack of adequate studies."

Need Legal Help Regarding Benicar Complications?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



Benicar Adverse ReactionsRSS Feed

Benicar High Blood Pressure Drug and Link to Serious Side Effects

Jan 6, 2017
Benicar is a commonly prescribed drug for individuals suffering from hypertension (high blood pressure), a condition impacting an estimated 67 million Americans. Benicar (olmesartan medoxomil) was approved by the U.S. Food and Drug Administration (FDA) in 2002 and belongs to the ARB (angiotensin receptor blocker) class of blood pressure medications. How Benicar Works Benicar works by blocking the activity of angiotensin-ll in the cardiovascular system. The liver generates angiotensin-ll, a...

Plaintiffs in Benicar MDL to File Motion for Partial Summary Judgment

Oct 6, 2016
Lawsuit To Alleging High Blood Pressure Medication Caused Intestinal Problem The Benicar multidistrict litigation (MDL) contains over 1,700 lawsuits alleging that the high blood pressure medication caused intestinal problems. Manufacturer Daiichi Sankyo allegedly knew about the risk of sprue-like enteropathy but failed to warn patients or their doctors about this information. The Benicar MDL is venued in the U.S. District Court for the District of New Jersey before U.S. District Judge Robert...

Benicar Lawsuit Alleges Physical and Psychological Damage

Sep 30, 2016
Blood Pressure Medications Caused Pshchological Damage And Injuries In a lawsuit against drug maker Daiichi Sankyo, a man alleges that the blood-pressure medication Benicar (olmesartan) caused him psychological damage and a variety of physical injuries. The lawsuit is a part of the multidistrict litigation (MDL) underway in New Jersey federal court, Top Class Actions reports. Nearly 1,700 similar lawsuits are currently in progress. The plaintiff, Danny, is 60 years old. He began taking...

More Benicar Adverse Reactions News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo